Tourmaline Bio, Inc. (NasdaqGM: TRML)
Health Care · Biotechnology · US
$—
— today · — 1Y
Tourmaline Bio, Inc. (NasdaqGM: TRML) operates in the Biotechnology industry within the Health Care sector.
trading between 20.00 and 48.27.
Tweenvest scores Tourmaline Bio, Inc. across four factors: quality 28/100. Its strongest factor is quality.
TRML price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.44
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $48.27
- 52-week low
- $20.00
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 74
- Next earnings
- —
About Tourmaline Bio, Inc.
Tourmaline Bio, Inc. is a clinical-stage biotechnology firm committed to advancing therapies for individuals suffering from debilitating immune disorders. The company's development pipeline focuses on conditions such as Atherosclerotic Cardiovascular Disease (ASCVD) and Thyroid Eye Disease (TED). Established in 2021, this enterprise is headquartered in New York, New York.
- ISIN
- US89157D1054
- Founded
- 2021
- Listed since
- May 7, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.